Pricing Log in Create free account
Friday 6 November 2026 Export SEPN’s income statement to Excel — free account

Septerna, Inc.

SEPN Healthcare Biotechnology

Septerna, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $46.0 million, up 4,174.5% from fiscal 2024.

Revenue
+22,375.6%
EPS
+48.2%
Free cash flow
−9.01%

Quarter to June 2026, against a year earlier

48.95 1.60 +3.38%
Market cap
$2.2B
P/E
0.0×
Fwd P/E
−32.6×
Dividend yield
—
F-score
5/9
Altman Z
3.41
Beneish M
32.85
Dividend safety
n/a
Overview
Financials
Income Statement Balance Sheet Cash Flow Metrics & Ratios

Septerna, Inc. (SEPN) Net income

Alert me on Net income

Septerna, Inc.'s net income for fiscal 2025 was −$48.9M, compared with −$71.8M in fiscal 2024. Over the twelve months to 30 June 2026 it was −$24.2M. Septerna, Inc. ranks 240th of 605 Biotechnology companies by net income.

Net income, annual

Embed this chart

Annual newest first

Period Net income Change
FY2025 −$48.9M —
FY2024 −$71.8M —
FY2023 $4.2M —

Quarterly newest first

Period Net income Change
Jun 2026 −$13.0M —
Mar 2026 −$8.6M —
Dec 2025 −$10.7M —
Sep 2025 $8.2M —
8 more quarters

Net income against peers

Company Net income
AUPH Aurinia Pharmaceuticals Inc compare $314.3M
VCEL Vericel Corporation compare $33.3M
SEPN Septerna, Inc. −$24.2M
PVLA Palvella Therapeutics, Inc. compare −$61.7M
ZYME Zymeworks Inc. compare −$150.0M
IMNM Immunome, Inc. compare −$254.3M
VERA Vera Therapeutics, Inc. compare −$401.9M
BHVN Biohaven Ltd. compare −$542.7M
LKFT Lakefront Biotherapeutics - Sponsored ADR compare −$652.4M

What Net income is

Net Income tells an investor how much profit a company kept in a period after every cost, interest charge and tax.

Reported line item

The full definition of Net income →

More on SEPN